DEVICE USER FEE LETTER AGREEMENT INCLUDES GUIDANCE DOCUMENTS
This article was originally published in The Gray Sheet
Executive Summary
DEVICE USER FEE LETTER AGREEMENT INCLUDES GUIDANCE DOCUMENTS that the agency commits to develop. Signed July 8 by FDA Commissioner David Kessler, the letter spells out performance goals that the agency agrees to meet after enactment of a device user fee bill. The letter, which will accompany user fee legislation expected to be introduced the week of July 11, was sent to Reps. John Dingell (D-Mich.), Henry Waxman (D-Calif.), Carlos Moorhead (R-Calif.) and Thomas Bliley (R-Va.).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.